An experimental treatment for Alzheimer's disease that was declared a failure in March has been brought back to life. Biotech giant Biogen and its partner Eisai plan to seek approval for the Alzheimer's treatment, aducanumab, from the US Food and Drug Administration in 2020. In March, the drugmakers had stopped most of its research efforts into aducanumab after findings from two trials showed that the drug wasn't showing signs that it was working.
An experimental treatment for Alzheimer's disease that was declared a failure in March has been brought back to life. Biotech giant Biogen and its partner Eisai plan to seek approval for the Alzheimer's treatment, aducanumab, from the US Food and Drug Administration in 2020. In March, the drugmakers had stopped most of its research efforts into aducanumab after findings from two trials showed that the drug wasn't showing signs that it was working.